PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
10.21203/rs.3.rs-1014277/v12021A multicenter, randomized, double-blind, placebo-controlled phase ii trial of intravenous inflammasome inhibitor (NuSepin) for the treatment of COVID-19 patientsSeung-Yong Seong, Seunghwa Leehttps://www.researchsquare.com/article/rs-1014277/v1, https://www.researchsquare.com/article/rs-1014277/v1.html
BMC Infectious Diseases10.1186/s12879-021-05983-22021211Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trialAmirreza Roostaei Firozabad, Zohreh Akhoundi Meybodi, Seyed Ruhollah Mousavinasab, Adeleh Sahebnasagh, Mohsen Gholinataj Jelodar, Iman Karimzadeh, Solomon Habtemariam, Fatemeh Saghafihttp://link.springer.com/content/pdf/10.1186/s12879-021-05983-2.pdf, http://link.springer.com/article/10.1186/s12879-021-05983-2/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12879-021-05983-2.pdf
10.21203/rs.3.rs-122376/v12021Efficacy and Safety of Levamisole Treatment in Clinical Presentations of Patients With COVID-19: A Double-Blind, Randomized, Controlled TrialAmir Roostaei, Zohre Akhoundi Meybodi, Seyed Rohollah Mosavinasab, Iman Karimzadeh, Adeleh Sahebnasagh, Mohsen Gholinataj, Fatemeh Saghafihttps://www.researchsquare.com/article/rs-122376/v1, https://www.researchsquare.com/article/rs-122376/v1.html
Journal of Hepatology10.1016/s0168-8278(05)81229-2199421S152Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen (TMX). Preliminary results of a randomized double-blind placebo-controlled trialhttps://api.elsevier.com/content/article/PII:S0168827805812292?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805812292?httpAccept=text/plain
Journal of Dentistry10.1016/j.jdent.2015.05.0112015438965-972Effectiveness of 6% hydrogen peroxide concentration for tooth bleaching—A double-blind, randomized clinical trialJ. Martín, P. Vildósola, C. Bersezio, A. Herrera, J. Bortolatto, J.R.C. Saad, O.B. Oliveira, E. Fernándezhttps://api.elsevier.com/content/article/PII:S0300571215001384?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0300571215001384?httpAccept=text/plain
International Immunopharmacology10.1016/j.intimp.2021.107871202198107871Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trialHossein Kasiri, Nima Rouhani, Ebrahim Salehifar, Monireh Ghazaeian, Sahar Fallahhttps://api.elsevier.com/content/article/PII:S1567576921005075?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1567576921005075?httpAccept=text/plain
Journal of the American Academy of Dermatology10.1016/j.jaad.2019.06.10982019814AB247Onset of treatment effectiveness with hydrogen peroxide topical solution 40% and 45% (w/w) in patients with seborrheic keratoses on the trunk, extremities and face: Results of a phase 2, randomized, double-blind, vehicle-controlled, parallel-group studyhttps://api.elsevier.com/content/article/PII:S0190962219320973?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0190962219320973?httpAccept=text/plain
European Heart Journal10.1093/eurheartj/ehaa934202041464387-4388Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment TrialLeonarda Galiuto, Carlo Patronohttp://academic.oup.com/eurheartj/article-pdf/41/46/4387/36177556/ehaa934.pdf, http://academic.oup.com/eurheartj/article-pdf/41/46/4387/36177556/ehaa934.pdf
Clinical Infectious Diseases10.1093/cid/ciab0562021Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”Julio C Alencar, Heraldo P Souzahttp://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab056/38501065/ciab056.pdf, http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab056/38501065/ciab056.pdf
10.21203/rs.3.rs-861831/v12021Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)Marvin R. McCreary, Patrick M. Schnell, Dale A. Rhodahttps://www.researchsquare.com/article/rs-861831/v1, https://www.researchsquare.com/article/rs-861831/v1.html